BioSpace News Archive

VYNE Therapeutics Inc. announced financial results for the quarter ended March 31, 2022 and provided a business update.

Actym Therapeutics announced the significant expansion of its senior leadership team.

Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported business highlights and financial results for the first quarter ended March 31, 2022.

BIOLASE, Inc., the global leader in dental lasers, announced its financial results for the first quarter ended March 31, 2022.

“With the accelerated FDA approval and U.S. commercial launch of VONJO, the first quarter was transformational for CTI and the myelofibrosis community.

Silverback Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Amylyx Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2022. “We are encouraged by the overall progress Amylyx made over the first quarter of 2022.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2022.

Cyclo Therapeutics, Inc. reported its financial results for the first quarter 2022 and provided a business update.

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2022, and provided clinical development and operational highlights.